8-K: Valion Bio Secures $50,000 in Series B Preferred Stock Financing

Valion Bio, Inc. has entered into a letter agreement with 3i, LP to issue 50 shares of Series B Preferred Stock and accompanying warrants for $50,000, furthering its financing efforts.

Summary

• Valion Bio, Inc. (the Company) entered into a Third Side Letter agreement with 3i, LP on October 7, 2026.
• Under this agreement, 3i, LP will purchase 50 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 1,539 shares of Common Stock.
• The aggregate purchase price for these securities is $50,000.
• These securities were issued under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506(b).
• This transaction is a part of a larger Series B Preferred Purchase Agreement initiated on April 29, 2025, and amended on December 9, 2025, which allows for up to $8,400,000 in aggregate purchases.
• The agreement is subject to certain conditions outlined in the Series B Preferred Purchase Agreement, including the listing of the Company's Common Stock on the Nasdaq Capital Market and compliance with its requirements.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, indicating continued investor confidence and operational progress, though the amount raised is modest.

Positives

• Secures additional funding of $50,000, demonstrating continued investor support.
• The transaction is part of an existing framework (Series B Preferred Purchase Agreement), suggesting ongoing investor commitment.
• The issuance of warrants provides potential for future capital infusion if exercised.
• The condition for Nasdaq listing indicates progress towards meeting exchange requirements, which is positive for liquidity and visibility.

Negatives

• The amount raised ($50,000) is relatively small in the context of the overall Series B financing potential ($8,400,000).
• The transaction is subject to the satisfaction of closing conditions, introducing a degree of uncertainty.
• The issuance of preferred stock and warrants can lead to future dilution for common stockholders.

Risks

• The company's ability to meet Nasdaq listing and maintenance requirements is a condition for closing.
• The forward-looking statements in the report are subject to substantial risks and uncertainties that could cause actual results to differ materially.
• Potential dilution to existing common stockholders from the conversion of preferred stock and exercise of warrants.

Future Outlook

The filing contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from management's estimates and expectations due to various known and unknown risks, uncertainties, and other factors. The company's ability to continue meeting Nasdaq listing requirements is a key factor.

Management Comments

• The company's actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.
• Future results are based upon management's best estimates based upon current conditions and the most recent results of operations.

Industry Context

StockSavvy.ai notes that securing even modest amounts of capital through preferred stock and warrants is a common strategy for biotechnology and life sciences companies, especially those in development stages, to fund ongoing operations and research while navigating the path to potential market listing and commercialization.

Comparison to Industry Standards

• The structure of this financing, involving preferred stock and warrants, is typical for early to mid-stage biotech companies seeking to bridge funding gaps.
• Companies in this sector often rely on multiple tranches of financing from specialized investors like 3i, LP, which may include venture capital or private equity firms focused on healthcare and technology.

Related Party Transactions

• The transaction involves 3i, LP, which is a party to multiple previous agreements with Valion Bio, Inc., including the Series B Preferred Purchase Agreement, Series C Preferred Purchase Agreement, and the issuance of a Senior Secured Convertible Note and warrant.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new preferred stock and warrants.
• Investors in 3i, LP will increase their stake in Valion Bio, Inc.
• The continued funding supports ongoing operations, potentially benefiting employees and future customers.

Next Steps

• Satisfy or waive the conditions set forth in the Third Side Letter and the Series B Preferred Purchase Agreement for the closing.
• Complete the issuance of 50 Series B Preferred Shares and Series B Warrants to 3i, LP.
• Continue to meet Nasdaq listing and maintenance requirements.

Key Dates

Recommendation

The filing indicates continued, albeit modest, financing activity and progress towards Nasdaq listing. However, the small amount raised and the inherent risks in the biotech sector warrant a cautious 'hold' recommendation until more substantial operational or financial milestones are achieved.

Keywords

Series B Preferred Stock, Warrants, Securities Purchase Agreement, Capital Raise, Convertible Preferred Stock, 3i, LP, Valion Bio, Nasdaq Listing